A 36-week three-center double-blind randomized cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo

Trial Profile

A 36-week three-center double-blind randomized cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2011

At a glance

  • Drugs Candesartan cilexetil; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Acronyms MEDICA
  • Most Recent Events

    • 01 Dec 2008 Results published in Hypertension, according to 1134299.
    • 15 Oct 2008 Checked against ClinicalTrials.gov record, last updated 15 October 2008.
    • 07 Sep 2008 Results reported at EASD 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top